DoD vaccine report
Executive Summary
Department of Defense report on production and acquisition of vaccines against biological agents will be delayed several months to allow DoD to consult with other agencies, including Office of Homeland Security. The report, originally due Feb. 1, was required under the DoD FY 2002 Authorization Act (1"The Pink Sheet" Oct. 8, 2001, p. 13)...
You may also be interested in...
Bioterrorism Vaccines: Liability Limits, Federalization Under Consideration
The Biotechnology Industry Organization is urging Congress to limit the liability of manufacturers who enter the vaccine production business in the interest of preparedness against potential bioterrorism attacks.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.